Status:
COMPLETED
Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia
Lead Sponsor:
All India Institute of Medical Sciences, Bhubaneswar
Conditions:
Schizophrenia
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
Schizophrenia (SCZ) is a chronic, severe and disabling mental disorder with unclear etiology and pathophysiology concerned with neuro-developmental,neurodegenerative abnormalities and cognitive impair...
Detailed Description
Schizophrenia (SCZ) is a chronic, severe and disabling mental disorder with unclear aetiology and pathophysiology concerned with neuro-developmental,neurodegenerative abnormalities and cognitive impai...
Eligibility Criteria
Inclusion
- All treatment naive patients clinically diagnosed first episode of SCZ according to ICD-10
- Patients of either sex with age range 18-45 years
- Treatment naïve patients
Exclusion
- Other Psychotic spectrum disorders (F21- F29)
- Highly agitated/ violent/ suicidal patients who need immediate treatment
- Patients with comorbid substance abuse except Nicotine use or history of organicity
- Patients with known history of diabetes mellitus, hypertension or any long standing significant medical illness/ significant neurological impairment/ clinical observable mental retardation
- Pregnant and nursing women
Key Trial Info
Start Date :
August 25 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 25 2018
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03304457
Start Date
August 25 2017
End Date
March 25 2018
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AIIMS
Bhubaneshwar, Odisha, India, 751019